Skip to content

Network of Cancer Research

Reliable, unbiased and up to date information in cancer research

Network of Cancer Research

Reliable, unbiased and up to date information in cancer research

  • Home
  • About
    • Home
    • ALK
NSCLC

Lorlatinib is an Orally Active ROS1/ALK Inhibitor for NSCLC Research

Louis Gilman July 21, 2023

ROS1 (c-ros oncogene 1) is a receptor tyrosine kinase encoded by the gene ROS1. Importantly, ROS1 is a proto-oncogene and highly expressed in a variety of tumor cell lines, belonging…

Cancer Idiopathic Pulmonary Fibrosis

Entrectinib is a Pan-Trk/ROS1/ALK Inhibitor for IPF and Solid Tumor Research

Louis Gilman July 18, 2023

Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive fibrosing interstitial pneumonia of unknown cause that occurs primarily in older adults. In addition, IPF is characterized by substantial…

Lung Cancer Lymphoma Non-Small Cell Lung Cancer

Repotrectinib is a potent ROS1 and TRK Inhibitor

Louis Gilman January 3, 2022

Repotrectinib is a potent ROS1 (IC50=0.07 nM) and TRK (IC50=0.83/0.05/0.1 nM for TRKA/B/C) inhibitor. The IC50 values are 0.83/0.05/0.1 nM for TRKA/B/C, respectively. Repotrectinib potently inhibits WT ALK (IC50=1.01 nM). Repotrectinib inhibits mutant ALKs. It inhibits…

Gastric Cancer

Crizotinib is an Orally Active, ATP-Competitive ALK and c-Met inhibitor

Louis Gilman November 13, 2021

In this article, we will introduce an orally bioavailable, ATP-competitive ALK and c-Met inhibitor, Crizotinib. The IC50 values for ALK and c-Met kinases are 20 and 8 nM, respectively. Additionally, in cell-based assays, Crizotinib…

Prostate Cancer

LDN193189 is a Selective BMP Type I Receptor Inhibitor

Louis Gilman April 10, 2021

Fibrodysplasia ossificans progressiva (FOP) is a congenital disorder of progressive. It is widespread postnatal ossification of soft tissues and is without known effective treatments. A recent study identified heterozygous mutations…

Lymphoma Non-Hodgkin Lymphoma

CJ-2360 is a Potent and Orally Active ALK Inhibitor

Louis Gilman January 11, 2021

Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase belonging to the insulin receptor (IR) kinase superfamily. It highly expresses in adult brain tissue and exerts an important role in…

Lymphoma PROTAC

TL13-12 is a Selective ALK-PROTAC Degrader

Louis Gilman April 21, 2020

Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase. ALK is an attractive target for cancer therapies not only for its prominent role in a number of malignancies but also…

Cancer PROTAC

TL13-112 is a PROTAC Degrader of ALK

Louis Gilman April 15, 2020

Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase and its mutation in domains. ALK Chromosomal translocations involve the kinase domain of ALK in many cancers. In addition to ALCL,…

Breast Cancer Lung Cancer

MS4077 is an Anaplastic Lymphoma Kinase PROTAC (Degrader)

Louis Gilman May 19, 2019

Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase, which belongs to the insulin receptor kinase subfamily. ALK correlates with oncogenesis in different types of cancers, such as anaplastic large-cell…

Recent Posts

  • BI 7446 is a STING Agonist for Immuno-oncology Research
  • JNJ-38877605 is an Orally Active c-Met Inhibitor for Solid Tumour Research
  • OATD-02 is an Orally Active Arginase 1/2 Inhibitor for Melanoma Research
  • INCB086550 is an Orally Active PD-L1 Inhibitor for Multiple Cancers Research
  • Panobinostat is a HDAC Inhibitor for Multiple Myeloma Research

Archives

  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019

Categories

  • Abdominal Aortic Aneurysm
  • Acute Leukemia
  • Acute Lymphoblastic Leukemia
  • Acute Myeloid Leukemia
  • Adenoid Cystic Carcinoma
  • Adenomyosis
  • Adrenocortical carcinoma
  • Adult T-cell leukemia/lymphoma
  • Anti-angiogenic
  • anti-inflammatory
  • antioxidant
  • autoimmune disease
  • B-cell malignancies
  • Bladder Cancer
  • Bone Cancer
  • Brain Cancer
  • Breast Cancer
  • Cancer
  • Cancer Metastases
  • Castration Resistant Prostate Cancer
  • ccRCC
  • Cervical Cancer
  • Cervix Cancer
  • Chemotherapy
  • Chemotherapy Side Effects
  • Cholangiocarcinoma
  • Chronic Lymphocytic Leukemia
  • Chronic Myeloid Leukemia
  • Colon Adenocarcinoma
  • Colon Cancer
  • Colorectal Cancer
  • Colorectal Cancer
  • Endometrial Adenocarcinoma
  • Endometrial Cancer
  • ER+ Breast Cancer
  • Esophageal Squamous Cell Carcinoma
  • Esophagus Cancer
  • Ewing's Sarcoma
  • Fibrosarcoma
  • Follicular Lymphoma
  • Gastric Adenocarcinoma
  • Gastric Cancer
  • Gastrointestinal Stromal Tumor
  • Glioblastoma
  • Glioblastoma Multiforme
  • Gliocytoma
  • Glioma
  • Head & Neck Cancer
  • Head and Neck Cancer
  • Hematologic Neoplasms
  • Hematological Malignancies
  • Hepatocellular carcinoma
  • HER2+ Breast Cancer
  • Hodgkin Lymphoma
  • HPV
  • HSV-1
  • Idiopathic Pulmonary Fibrosis
  • Kaposi's Sarcoma
  • Kidney Cancer
  • Large B Cell Lymphoma
  • Large B-cell Lymphoma
  • Large Cell Lung Cancer
  • Leukemia
  • Liver Cancer
  • Lung Adenocarcinoma
  • Lung Cancer
  • Lymphoma
  • Malaria
  • Mantle Cell Lymphoma
  • Medullary Thyroid Carcinoma
  • Medulloblastoma
  • Medulloblastomas
  • Megakaryoblastic Leukemia
  • Melanoma
  • Mesothelioma
  • Metabolism
  • Metabolism-related diseases
  • Metastatic Castration-resistant Prostate Cancer
  • Multiple Myeloma
  • Myelodysplastic Syndrome
  • Myelodysplastic Syndrome
  • Myeloma
  • Nasopharyngeal Carcinoma
  • Neoplasms
  • Neuroblastoma
  • Neuroendocrine Tumors
  • Neuropathy
  • Non-Hodgkin Lymphoma
  • Non-Small Cell Lung Cancer
  • NSCLC
  • NUT midline carcinoma
  • Obesity
  • Oesophageal Cancer
  • Oral Carcinoma
  • Osteosarcoma
  • Ovary Cancer
  • Pancreas Cancer
  • Pancreatic cancer
  • Pancreatic Ductal Adenocarcinoma
  • Ph+ ALL
  • Philadelphia-positive Leukemias
  • Plasmacytoma
  • Prostate Cancer
  • PROTAC
  • Renal Carcinoma
  • Sarcoma
  • Skin Cancer
  • Small Cell Lung Cancer
  • Soft Tissue Tumor
  • Solid Tumors
  • Squamous Carcinoma
  • T Acute Lymphoblastic Leukemia
  • T-cell Lymphoma
  • Thyroid Cancer
  • Triple-Negative Breast Cancer
  • uncategorized
  • Uterine Serous Carcinoma

You Missed

Breast Cancer

BI 7446 is a STING Agonist for Immuno-oncology Research

Gastric Cancer Obesity

JNJ-38877605 is an Orally Active c-Met Inhibitor for Solid Tumour Research

Multiple Myeloma Myeloma

OATD-02 is an Orally Active Arginase 1/2 Inhibitor for Melanoma Research

autoimmune disease

INCB086550 is an Orally Active PD-L1 Inhibitor for Multiple Cancers Research

Network of Cancer Research

Reliable, unbiased and up to date information in cancer research

Copyright © All rights reserved | Blogus by Themeansar.